NCT06366945 is a Phase 2 clinical trial of Carboplatin in Head and Neck Squamous Cell Carcinoma, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Who is sponsoring NCT06366945?

NCT06366945 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

What drugs are being tested in NCT06366945?

Interventions in NCT06366945: Carboplatin, Tislelizumab, Polymeric Micellar Paclitaxel, Surgical Resection of Primary +/- Neck Dissection, Post-operative radiation therapy.

What condition does NCT06366945 study?

NCT06366945 studies Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC, Head Cancer Neck.

Is NCT06366945 still recruiting?

NCT06366945 is currently not yet recruiting. Last updated 16 April 2024.

Last reviewed 2024-04-16 · How we verify

NCT06366945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Not yet recruiting Phase 2 Last updated 16 April 2024

What this trial tests

Phase 2 trial testing Carboplatin in Head and Neck Squamous Cell Carcinoma in 85 participants. Not yet recruiting.

Timeline

20 April 2024

Primary endpoint
30 December 2026

30 May 2029

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	85
Start date	20 April 2024
Primary completion	30 December 2026
Estimated completion	30 May 2029

Drugs / interventions tested

Carboplatin (Carboplatin) — full drug profile →
Tislelizumab (TISLELIZUMAB) — full drug profile →
Polymeric Micellar Paclitaxel — full drug profile →
Surgical Resection of Primary +/- Neck Dissection
Post-operative radiation therapy

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Head and Neck Cancer — all drugs for Head and Neck Cancer →
HNSCC — all drugs for HNSCC →
Head Cancer Neck — all drugs for Head Cancer Neck →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 75, any sex, with Head and Neck Squamous Cell Carcinoma or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficiency and safety of Tislelizumab combinated with carboplatin and polymeric micellar paclitaxel as a new neoadjuvant treatment regimen for resectable HNSCC patients with clinical positive lymph node metastasis

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials.
Serras A, Faustino C, Pinheiro L. · · 2024 · cited 4× · PMID 39204392 · DOI 10.3390/pharmaceutics16081047
Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.
Shiridokht F, Kehtari P, Eskandani M, Farajollahi A, et al · · 2025 · PMID 41189671 · DOI 10.1016/j.ijpx.2025.100419
Recent advances in tumor targeted polymeric nanoparticles for HNC treatment: Enhancing therapeutic efficacy via engineered and biocompatible drug delivery systems.
Srinivasan MK, Prasad M. · · 2025 · PMID 40895268 · DOI 10.1016/j.jobcr.2025.08.012

Verify or expand the search:

Other trials of Carboplatin

Trials testing the same drug.

NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06366945 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Last refreshed: 16 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06366945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing